Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Ovarian Neoplasms

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 23 articles: HTML format Text format

Single Articles

January 2012
1. LU JF , Rasmussen E, Karlan BY, Vergote IB, et al
   Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.
   Cancer Chemother Pharmacol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   December 2011
2. BJORKLUND M , Roos J, Gogvadze V, Shoshan M, et al
   Resveratrol induces SIRT1- and energy-stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment.
   Cancer Chemother Pharmacol. 2011;68:1459-67.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   November 2011
3. ZAMBONI WC , Combest AJ, DeLoia JA, Edwards RP, et al
   Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer.
   Cancer Chemother Pharmacol. 2011;68:1255-62.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   October 2011
4. KANATANI I , Lin X, Yuan X, Manorek G, et al
   Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin.
   Cancer Chemother Pharmacol. 2011;68:979-90.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   September 2011
5. PIGNATA S , Amant F, Scambia G, Sorio R, et al
   A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy.
   Cancer Chemother Pharmacol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   July 2011
6. WILMES A , O'Sullivan D, Chan A, Chandrahasen C, et al
   Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells.
   Cancer Chemother Pharmacol. 2011;68:117-26.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   April 2011
7. MUNOZ-CASARES FC , Rufian S, Arjona-Sanchez A, Rubio MJ, et al
   Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study.
   Cancer Chemother Pharmacol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. GARG MB , Ackland SP
   Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect.
   Cancer Chemother Pharmacol. 2011;67:963-6.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   March 2011
9. GUO AM , Liu X, Al-Wahab Z, Maddippati KR, et al
   Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival.
   Cancer Chemother Pharmacol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   February 2011
10. AHMED AA , Goldsmith J, Fokt I, Le XF, et al
    A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer.
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. SHAH DK , Veith J, Bernacki RJ, Balthasar JP, et al
    Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer.
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
12. TUMMALA R , Diegelman P, Hector S, Kramer DL, et al
    Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
    Cancer Chemother Pharmacol. 2011;67:401-14.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2010
13. ANDREOPOULOU E , Chen T, Liebes L, Curtin J, et al
    Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer.
    Cancer Chemother Pharmacol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
14. JAIN D , Patel N, Shelton M, Basu A, et al
    Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression.
    Cancer Chemother Pharmacol. 2010;66:945-52.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
15. DE STEFANO I , Battaglia A, Zannoni GF, Prisco MG, et al
    Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts.
    Cancer Chemother Pharmacol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. OGURI T , Shimokata T, Inada M, Ito I, et al
    Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis.
    Cancer Chemother Pharmacol. 2010;66:813-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2010
17. GREENE DP , Ferriss JS, Jazaeri AA
    Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report.
    Cancer Chemother Pharmacol. 2010;66:265-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. LEE SJ , Lee J, Lim HY, Kang WK, et al
    Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis.
    Cancer Chemother Pharmacol. 2010;66:229-35.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2010
19. FENG Z , Zhao G, Yu L, Gough D, et al
    Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane.
    Cancer Chemother Pharmacol. 2010;65:923-30.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. JANJIGIAN YY , Lee W, Kris MG, Miller VA, et al
    A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors.
    Cancer Chemother Pharmacol. 2010;65:833-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2010
21. XENIDIS N , Neanidis K, Amarantidis K, Dimopoulos P, et al
    Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer.
    Cancer Chemother Pharmacol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. POLCHER M , Eckhardt M, Coch C, Wolfgarten M, et al
    Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Cancer Chemother Pharmacol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2010
23. KUROKAWA T , He G, Siddik ZH
    Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner.
    Cancer Chemother Pharmacol. 2010;65:427-36.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: